Although shock therapy is effective in terminating ventricular tachycardia (VT), it can be painful to the patient and repetitive shocks can decrease a patient's quality of life. Previous studies have suggested that one or more sets of aggressive device parameter settings may reduce the total number of shocks in primary prevention patients. In addition to shock therapies, antitachycardia pacing (ATP) is also available in ICDs to treat VT. The PROVIDE trial aims to prospectively study the effect of high detection rates, prolonged detection intervals, aggressive SVT discriminators, and extensive ATP therapy in prolonging the time to first shock in primary prevention patients.
Study Type
OBSERVATIONAL
Enrollment
1,670
Cardiac device
Hall-Garcia Cardiology Associates
Houston, Texas, United States
The primary endpoint of this study is the rate of first shock
Time frame: Average follow-up period is 530 days
The primary safety endpoint of this study is the rate of arrhythmic syncope
Time frame: Average follow-up period is 530 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.